Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMT, Reactivation of Embryonic Transcription Factors and Alteration of the miR Signaling Network as Pronostic and Predictive Markers in Lung Cancer

NCT03509779 is registered in ClinicalTrials.gov with European Georges Pompidou Hospital as lead sponsor.

NCT NCT03509779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03509779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMT, Reactivation of Embryonic Transcription Factors and Alteration of the miR Signaling Network as Pronostic and Predictive Markers in Lung Cancer
Lead sponsor
European Georges Pompidou Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 20, 2014
Completion date
December 31, 2025
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial mesenchymal transition, nsclc, stage i, ii, iiia, iiib, progression, surgery